Literature DB >> 19505389

Reciprocal modulation of circulating CD4+CD25+bright T cells induced by extracorporeal photochemotherapy in cutaneous T-cell lymphoma and chronic graft-versus-host-disease patients.

P Quaglino1, A Comessatti, R Ponti, A Peroni, F Mola, M T Fierro, P Savoia, M Novelli, M G Bernengo.   

Abstract

The mechanisms of action of extracorporeal photochemotherapy (ECP) in cutaneous T-cell lymphoma (CTCL) are poorly understood. Recently, ECP has been shown to induce an increase in regulatory T cell (Treg) expression and functional activities in Graft-versus-host-disease (GvHD), whereas no data are available in CTCL patients. The aim of this study is to evaluate whether ECP is able to modulate the expression levels of the circulating CD4+CD25+bright subset in CTCL patients and whether these modifications are related to the disease course. The patient population included 43 CTCL and 15 chronic GvHD patients treated by ECP at our institutions since 1992. The expression of the circulating CD4+CD25+bright subset was analysed at baseline and sequentially during treatment by flow-cytometry. Fifty healthy donors were used as controls. The baseline circulating CD4+CD25+bright percentage values in CTCL (median: 4.3 percent) were similar to those of healthy donors, whereas GvHD showed significantly lower values (median: 1.5 percent; p<0.001). During treatment, CTCL patients were characterised by an early decrease (from 4.3 percent to 2.4 percent median after 6 months). The CD4+CD25+bright decrease was associated to the disease course, as it occurred in 91.3 percent of responding but in only 25 percent of PD patients (p=0.0001). On the other hand, a significant increase of CD4+CD25+bright cells was observed in GvHD. ECP induces a reciprocal modulation of the circulating CD4+CD25+bright cells in CTCL and GvHD, with a downregulation in CTCL potentially associated with the response mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505389     DOI: 10.1177/039463200902200212

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  6 in total

Review 1.  [Update on extracorporeal photopheresis].

Authors:  U Just; R Knobler
Journal:  Hautarzt       Date:  2015-11       Impact factor: 0.751

2.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

Review 3.  Extracorporeal photopheresis as a therapy for autoimmune diseases.

Authors:  Zoya Kuzmina; David Stroncek; Steven Z Pavletic
Journal:  J Clin Apher       Date:  2014-12-26       Impact factor: 2.821

Review 4.  The four types of Tregs in malignant lymphomas.

Authors:  Jing Wang; Xiao-Yan Ke
Journal:  J Hematol Oncol       Date:  2011-12-09       Impact factor: 17.388

5.  Photopheresis efficacy in the treatment of rheumatoid arthritis: a pre-clinical proof of concept.

Authors:  Céline Coppard; Francis Bonnefoy; Dalil Hannani; Françoise Gabert; Olivier Manches; Joel Plumas; Sylvain Perruche; Laurence Chaperot
Journal:  J Transl Med       Date:  2019-09-18       Impact factor: 5.531

6.  European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.

Authors:  R Knobler; P Arenberger; A Arun; C Assaf; M Bagot; G Berlin; A Bohbot; P Calzavara-Pinton; F Child; A Cho; L E French; A R Gennery; R Gniadecki; H P M Gollnick; E Guenova; P Jaksch; C Jantschitsch; C Klemke; J Ludvigsson; E Papadavid; J Scarisbrick; T Schwarz; R Stadler; P Wolf; J Zic; C Zouboulis; A Zuckermann; H Greinix
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-10-06       Impact factor: 6.166

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.